Annual, English, IR, Listing Regulation, News, Regulatory, Report

Acarix AB’s Annual Report 2024

  • Posted by author-avatar
15 Apr

Acarix, a global leader in AI and advanced acoustic-based cardiac diagnostics, today announces that the Annual Report for 2024 is available as a pdf on the company’s website,

https://www.acarix.com/for-investors/financial-reports-and-calendar


The Annual Report is available in Swedish and English.

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

For more information, contact
Ashley Wilson, phone +1405 413 5201, email awilson@saxum.com

Attachments
Acarix AnnualReport English 2024

Acarix AnnualReport English 2024
Back to list
Older NOTICE OF ANNUAL GENERAL MEETING IN Acarix AB